Aldosterone Synthase Inhibition With Lorundrostat for Uncontrolled Hypertension
Luke J. Laffin(Cleveland Clinic), Larkin T. Wadsworth(Target (United States)), Lon Lynn(Launchpad Central (United States)), Mark Kleiner(Target (United States)), Glenn Gould(Target (United States)), Frank Cole(Target (United States)), Brian Taylor Slingsby, Leonard Dunn(Target (United States)), Jeffrey B. Rosen(Target (United States)), David Rodman, Matthew Hong(Target (United States)), Bruce Iteld(Target (United States)), Natasa Rajicic(Cytel (United States)), Matthew R. Weir(University of Maryland, Baltimore), Gilbert Ledesma(Target (United States)), Michael P. Carroll(Target (United States)), Steven E. Nissen(Cleveland Clinic), William Eaves(Target (United States)), Ronald Surowitz(Target (United States)), Keung Lee(Launchpad Central (United States)), Andres Patron(Launchpad Central (United States)), Valentine M. Ebuh(Target (United States)), Yaa Oppong(Target (United States)), Richard Beasley(Medical Research Institute of New Zealand), Anand Vaidya(Brigham and Women's Hospital), M Pan Alvarez Osorio(Target (United States)), Joseph Lambert(Target (United States)), Obadias Marquez(Target (United States)), Walter Pharr(Target (United States)), Matthew J. Budoff(The Lundquist Institute), Charles Kemp(Target (United States)), David P. Morin(Target (United States)), John Lentz(Launchpad Central (United States)), Issac Sachmechi(Target (United States)), Lilia Rodriguez-Ables(Target (United States)), Anil Chhabra(Target (United States)), C Kennelly(Target (United States)), Mahendra Jain(Target (United States)), José Yépez(Target (United States)), Roger Estevez(Target (United States)), Mercedes Ponce de Leon(Target (United States)), Joel Neutel(Target (United States)), George Carr(Target (United States)), Steven Lupovitch(Target (United States)), Mark E Kutner(Target (United States)), Mobeen Mazhar(Target (United States)), James M. Luther(Vanderbilt University)
Cited by 187
Related Papers
Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes
|New England Journal of Medicine|2007|4.7k
Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis
|New England Journal of Medicine|2016|846
2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials
|Circulation|2018|712